Xbiotech Stock Today

XBIT Stock  USD 7.99  0.02  0.25%   

Performance

19 of 100

 
Low
 
High
Solid

Odds Of Distress

Less than 29

 
100  
 
Zero
Below Average
XBiotech is selling for under 7.99 as of the 28th of March 2024; that is 0.25 percent up since the beginning of the trading day. The stock's last reported lowest price was 7.81. XBiotech has about a 29 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat solid performance during the last 90 days. Equity ratings for XBiotech are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of February 2024 and ending today, the 28th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
15th of April 2015
Category
Healthcare
Classification
Health Care
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company was incorporated in 2005 and is headquartered in Austin, Texas. Xbiotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 30.45 M outstanding shares of which 585.31 K shares are at this time shorted by private and institutional investors with about 9.91 trading days to cover. More on XBiotech

Moving together with XBiotech Stock

  0.89EQ Equillium Financial Report 9th of May 2024 PairCorr
  0.8MDWD Mediwound Financial Report 4th of June 2024 PairCorr

Moving against XBiotech Stock

  0.83MEIP MEI Pharma Financial Report 9th of May 2024 PairCorr
  0.83DBVT DBV Technologies Financial Report 2nd of May 2024 PairCorr
  0.82KA Kineta Inc Report 29th of March 2024 PairCorr
  0.81MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr
  0.8VALN Valneva SE ADR Financial Report 2nd of May 2024 PairCorr
  0.74TFX Teleflex Incorporated Financial Report 2nd of May 2024 PairCorr
  0.67CALT Calliditas Therapeutics Financial Report 21st of May 2024 PairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

XBiotech Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. XBiotech's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding XBiotech or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ChairmanJohn Simard
Thematic IdeaCancer Fighters (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Financial Strength
Based on the key indicators obtained from XBiotech's historical financial statements, XBiotech is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. Financial strength of XBiotech is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.01780.0187
Notably Down
Slightly volatile
Gross Profit Margin0.460.75
Way Down
Slightly volatile
Total Current Liabilities9.4 M6.1 M
Way Up
Pretty Stable
Non Current Liabilities Total2.4 M2.3 M
Sufficiently Up
Slightly volatile
Total Assets209.4 M227.2 M
Significantly Down
Slightly volatile
Total Current Assets179.8 M201.7 M
Fairly Down
Slightly volatile
XBiotech's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to XBiotech's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand XBiotech's financial leverage. It provides some insight into what part of XBiotech's total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on XBiotech's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how XBiotech deploys its capital and how much of that capital is borrowed.
Liquidity
XBiotech cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company has a current ratio of 28.41, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist XBiotech until it has trouble settling it off, either with new capital or with free cash flow. So, XBiotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like XBiotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for XBiotech to invest in growth at high rates of return. When we think about XBiotech's use of debt, we should always consider it together with cash and equity.

Total Cash From Operating Activities

(19.66 Million)
XBiotech (XBIT) is traded on NASDAQ Exchange in USA. It is located in 5217 Winnebago Lane, Austin, TX, United States, 78744 and employs 82 people. XBiotech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 243 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate XBiotech's market, we take the total number of its shares issued and multiply it by XBiotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. XBiotech conducts business under Biotechnology sector and is part of Health Care industry. The entity has 30.45 M outstanding shares of which 585.31 K shares are at this time shorted by private and institutional investors with about 9.91 trading days to cover. XBiotech currently holds about 225.79 M in cash with (18.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.42.
Check XBiotech Probability Of Bankruptcy
Ownership Allocation
XBiotech retains a total of 30.45 Million outstanding shares. XBiotech owns significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company shows, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check XBiotech Ownership Details

XBiotech Stock Price Odds Analysis

Attributed to a normal probability distribution, the odds of XBiotech jumping above the current price in 90 days from now is about 1.16%. The XBiotech probability density function shows the probability of XBiotech stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days XBiotech has a beta of -1.0859. This entails Moreover, xBiotech has an alpha of 1.3172, implying that it can generate a 1.32 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 7.99HorizonTargetOdds Above 7.99
98.83%90 days
 7.99 
1.16%
Based on a normal probability distribution, the odds of XBiotech to move above the current price in 90 days from now is about 1.16 (This XBiotech probability density function shows the probability of XBiotech Stock to fall within a particular range of prices over 90 days) .

XBiotech Stock Institutional Holders

Institutional Holdings refers to the ownership stake in XBiotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of XBiotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing XBiotech's value.
InstituionRecorded OnShares
Man Group Plc2023-12-31
58.4 K
State Street Corporation2023-12-31
56.5 K
Qube Research & Technologies2023-12-31
56.5 K
Bank Of New York Mellon Corp2023-12-31
55.7 K
Susquehanna International Group, Llp2023-12-31
37.4 K
Two Sigma Investments Llc2023-12-31
25.4 K
Two Sigma Advisers, Llc2023-12-31
24 K
Fmr Inc2023-12-31
20 K
Squarepoint Ops Llc2023-12-31
18.9 K
Vanguard Group Inc2023-12-31
881.5 K
Millennium Management Llc2023-12-31
795.7 K
View XBiotech Diagnostics

XBiotech Historical Income Statement

XBiotech Income Statement is one of the three primary financial statements used for reporting XBiotech's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of XBiotech revenue and expense. XBiotech Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, XBiotech's Depreciation And Amortization is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 7.9 M in 2024, whereas Operating Income is likely to drop (39.4 M) in 2024. View More Fundamentals

XBiotech Stock Against Markets

Picking the right benchmark for XBiotech stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in XBiotech stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for XBiotech is critical whether you are bullish or bearish towards XBiotech at a given time. Please also check how XBiotech's historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in XBiotech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bonds Directory Now

   

Bonds Directory

Find actively traded corporate debentures issued by US companies
All  Next Launch Module

XBiotech Corporate Directors

XBiotech corporate directors refer to members of a XBiotech board of directors. The board of directors generally takes responsibility for the XBiotech's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of XBiotech's board members must vote for the resolution. The XBiotech board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Peter LibbyDirectorProfile
JanPaul WaldinIndependent DirectorProfile
Daniel VasellaLead Independent DirectorProfile
Michael StecherMedical DirectorProfile

How to buy XBiotech Stock?

Before investing in XBiotech, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in XBiotech. To buy XBiotech stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of XBiotech. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase XBiotech stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located XBiotech stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased XBiotech stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as XBiotech, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy XBiotech Stock please use our How to Invest in XBiotech guide.

Already Invested in XBiotech?

The danger of trading XBiotech is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of XBiotech is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than XBiotech. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile XBiotech is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether XBiotech is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if XBiotech Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Xbiotech Stock. Highlighted below are key reports to facilitate an investment decision about Xbiotech Stock:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XBiotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy XBiotech Stock please use our How to Invest in XBiotech guide.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for XBiotech Stock analysis

When running XBiotech's price analysis, check to measure XBiotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XBiotech is operating at the current time. Most of XBiotech's value examination focuses on studying past and present price action to predict the probability of XBiotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XBiotech's price. Additionally, you may evaluate how the addition of XBiotech to your portfolios can decrease your overall portfolio volatility.
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Stocks Directory
Find actively traded stocks across global markets
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Is XBiotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XBiotech. If investors know XBiotech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XBiotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.81)
Revenue Per Share
0.01
Quarterly Revenue Growth
(0.93)
Return On Assets
(0.1)
Return On Equity
(0.11)
The market value of XBiotech is measured differently than its book value, which is the value of XBiotech that is recorded on the company's balance sheet. Investors also form their own opinion of XBiotech's value that differs from its market value or its book value, called intrinsic value, which is XBiotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XBiotech's market value can be influenced by many factors that don't directly affect XBiotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XBiotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if XBiotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XBiotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.